Transgene to Showcase Novel Oncolytic Virus Data at SITC 2026…

Event summary

Transgene will present preclinical data on PoxSTG-EEV, a novel enveloped oncolytic virus, at SITC 2026.
The poster, titled 'PoxSTG-EEV: a Novel Enveloped Virion–Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery,' will be presented on November 7, 2026.
The abstract will be available on the SITC website on November 3, 2026, at 9 a.m. ET.
Transgene's myvac® platform is designed to develop individualized neoantigen therapeutic vaccines (INTVs).
TG4050 and TG4070 are the Company’s lead assets based on the myvac® platform.

The big picture

Transgene's presentation at SITC 2026 highlights its focus on developing novel virus-based immunotherapies. The company's myvac® platform and oncolytic virus programs position it within the competitive landscape of cancer immunotherapy, where systemic delivery of oncolytic viruses remains a key challenge. The success of PoxSTG-EEV could potentially open new avenues for treating solid tumors, aligning with broader industry trends towards personalized and targeted cancer therapies.

What we're watching

Clinical Translation: How preclinical data on PoxSTG-EEV will translate into clinical efficacy and safety.
Market Positioning: Whether Transgene can leverage this novel oncolytic virus to strengthen its position in the cancer immunotherapy space.
Regulatory Pathway: The pace at which Transgene can advance PoxSTG-EEV through regulatory approvals.